Dr. Karim Dabbagh to Present at GTCbio’s 3rd Protein Kinase in Drug Discovery Conference on May 5-6

Monrovia, CA, March 30, 2008 --(PR.com)-- Dr. Dabbagh’s presentation will cover P38 MAP Kinases and the important roles they play in inflammatory responses. Since P38 MAP Kinases are involved in the generation, as well as the signaling pathways of pro-inflammatorycytokines such as TNF- and IL-1, therapeutic targeting of P38 MAP kinase has been an area of intense pre-clinical and clinical research. Dr. Dabbagh’s presentation will provide preclinical data for P38 inhibitors, the selectivity profile of these inhibitors as well as the safety and efficacy of the P38 inhibitors. The clinical applications of these inhibitors will also be discussed.

GTCbio’s 3rd Protein Kinase in Drug Discovery Conference will take place on May 5-6, 2008 in San Diego, CA and will cover Kinase Drug Design, Kinase Targets and Inhibitors in CNS Disorders, Oncology, and Inflammatory Disorders, as well as New Technologies in Screening and Identifying Targets and Inhibitors.

The conference also features presentations from other leading organizations such as Johnson & Johnson, Roche, Pfizer, Merck, GlaxoSmithKline, Salk Institute, AstraZeneca, Methylgene, UCSD, and many more.

For more information including a detailed agenda, exhibitor opportunities and registration information call 626-256-6405 or visit them at gtcbio.com

About GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Their goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com

###